Will Garner

1.4k citations

29 papers · 833 · 1 hit paper · h-index 11

Impact in

Virology top 5%
- HIV Research and Treatment
Infectious Diseases top 5%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in

Infectious Diseases 13
- HIV/AIDS drug development and treatment 12
Hepatology 6
- Liver Diseases and Immunity 5

Co-authors: Anton Louis Pozniak (4 shared papers)Kirsten White (5 shared papers)Erin K. Quirk (3 shared papers)Andrew Cheng (2 shared papers)Andrea Antinori (4 shared papers)Hans-Jürgen Stellbrink (2 shared papers)Kimberly Workowski (1 shared paper)Edwin DeJesus (1 shared paper)
Journals: Journal of the International AIDS Society (3 papers)Patient (3 papers)Journal of Hepatology (3 papers)AIDS (3 papers)Digestive and Liver Disease (2 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Will Garner

27 papers receiving 819 citations

Will Garner's Hit Papers

align trajectories log scale

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial 2017 · 307 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2017 The Lancet

Peers

Countries citing papers authored by Will Garner

Since Specialization

Citations

This map shows the geographic impact of Will Garner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Will Garner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Will Garner more than expected).

Fields of papers citing papers by Will Garner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Will Garner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Will Garner. The network helps show where Will Garner may publish in the future.

Co-authors

The 25 scholars most cited alongside Will Garner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Will Garner Line = papers co-authored together Will Garner links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial The Lancet ·Paul Edward Sax, Anton Louis Pozniak, Marisa Montes, Ellen Koenig, Edwin DeJesus, Hans-Jürgen Stellbrink, Andrea Antinori, Kimberly Workowski, Jihad Slim, Jacques Reynes, Will Garner, Joseph M. Custodio, Kirsten White, Devi SenGupta, Andrew Cheng, Erin K. Quirk Hit paper breakdown →	2017	307
2	Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study The Lancet ·Emmanuel M. Gonzales, Winita Hardikar, Michael Stormon, Alastair Baker, Loreto Hierro, Dorota Gliwicz, Florence Lacaille, Alain Lachaux, Ekkehard Sturm, Kenneth D.R. Setchell, Ciara Kennedy, Alejandro Dorenbaum, Jana I. Steinmetz, Nirav K. Desai, Andrew James Wardle, Will Garner, Pamela Vig, Thomas Jaecklin, Etienne Marc Sokal, Emmanuel Jacquemin	2021	115
3	Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial The Lancet Infectious Diseases ·Anton Louis Pozniak, Martin H. Markowitz, Anthony Mills, Hans‐Juergen Stellbrink, Antonio Antela, Peré Domingo, Pierre‐Marie Girard, Keith Henry, Thai Nguyen, David M. Piontkowsky, Will Garner, Kirsten White, Bill Guyer	2014	78
4	Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults JAIDS Journal of Acquired Immune Deficiency Syndromes ·Joel E. Gallant, Jason M. Brunetta, Gordon E. Crofoot, Paul M. Benson, Anthony Mills, Cynthia Brinson, Shinichi Oka, Andrew Cheng, Will Garner, Marshall W. Fordyce, Moupali Das, Scott H. McCallister, (unknown)	2016	48
5	Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies HIV Clinical Trials ·Mark Richard Nelson, Richard Elion, C Cohen, Anthony Mills, Sally Hodder, Sorana Segal-Maurer, Mark Theo Bloch, Will Garner, Bill Guyer, Scott Williams, S.K. Chuck, Simon Vanveggel, Henri Deckx, Marita Stevens	2013	48
6	Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study Hepatology Communications ·Kathleen M. Loomes, Robert H. Squires, Deirdre Anne Kelly, Sanjay R. Rajwal, Nisreen Soufi, Alain Lachaux, Irena Jankowska, Cara L. Mack, Kenneth D.R. Setchell, Palaniswamy Karthikeyan, Ciara Kennedy, Alejandro Dorenbaum, Nirav K. Desai, Will Garner, Thomas Jaecklin, Pamela Vig, Alexander Gerhard Miethke, Richard J. Thompson	2022	47
7	Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine Patient ·David Alain Wohl, Amanda Clarke, Franco Maggiolo, Will Garner, Marianne Laouri, Hal Martin, Erin K. Quirk	2018	44
8	Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults AIDS ·Jan van Lunzen, Andrea Antinori, Calvin J. Cohen, José Ramón Arribas, David Alain Wohl, Armin Rieger, Anita Rachlis, Mark Theo Bloch, Sorana Segal-Maurer, Will Garner, Danielle Porter, Matthew Bosse, David M. Piontkowsky, Susan K. Chuck, Shampa De-Oertel	2015	32
9	Maralixibat Treatment Response in Alagille Syndrome is Associated with Improved Health-Related Quality of Life The Journal of Pediatrics ·Binita Maya Kamath, Andrea Goldstein, Robin Howard, Will Garner, Pamela Vig, Jessica R. Marden, Emma Billmyer, Annika Anderson, Noam Y. Kirson, Emmanuel Jacquemin, Emmanuel M. Gonzales	2022	19
10	Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment AIDS Care ·Ed L. Wilkins, Calvin J. Cohen, Benoît Trottier, Stefan Eßer, Don E. Smith, Bernhard J. Haas, Cynthia Brinson, Will Garner, Susan K. Chuck, DE Thorpe, Shampa De-Oertel	2015	17
11	Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor Hepatology ·Ronald J. Sokol, Emmanuel M. Gonzales, Binita Maya Kamath, Alastair Baker, Pamela Vig, Douglas B. Mogul, Will Garner, Bettina E. Hansen, Emmanuel Jacquemin, Richard J. Thompson	2023	13
12	Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF Patient ·Anthony Mills, Will Garner, Anton Louis Pozniak, Juan Berenguer, Rebecca M. Speck, Randall H. Bender, Thai Nguyen	2015	11
13	Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF Patient ·Joseph Gathe, José Ramón Arribas, Jan van Lunzen, Will Garner, Rebecca M. Speck, Randall H. Bender, Sanatan Shreay, Thai Nguyen	2015	11
14	Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen AIDS ·Giuliano Rizzardini, Andrea Gori, Celia Miralles, Julián Olalla, Jean‐Michel Molina, François Raffi, Princy N. Kumar, Andrea Antinori, Moti N. Ramgopal, Hans-Jürgen Stellbrink, Moupali Das, Hoa Chu, Renee R. Ram, Will Garner, Yongwu Shao, Susan K. Chuck, David M. Piontkowsky, Richard Haubrich	2019	7
15	A Double-Blind, Multicentre, Randomised, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of Invasive Fungal Infections in Subjects Receiving Remission-Induction Chemotherapy for Acute Lymphoblastic Leukaemia (AmBiGuard trial) Blood ·Oliver A. Cornely, T. Leguay, Johan A. Maertens, Carlo Castagnola, Αchilles Anagnostopoulos, Bernadino Allione, Claus Peter Heußel, J. Peter Donnelly, Samir G. Agrawal, Will Garner, Catherine Simcock, Michael Hawkins, Nicola Goekbuget	2014	6
16	Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY‐NNRTI subgroup analysis Journal of the International AIDS Society ·Hans‐Juergen Stellbrink, Andrea Antinori, Anton Louis Pozniak, Jason Flamm, Fritz Bredeek, Kiran Patel, Will Garner, David M. Piontkowsky	2014	6
17	Colchicine for Familial Mediterranean Fever (Periodic Peritonitis) — Concl. New England Journal of Medicine ·Will Garner	1974	6
18	Simplification to Stribild vs continuation of RTV‐boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY‐PI subgroup analysis Journal of the International AIDS Society ·José Ramón Arribas, Giuliano Rizzardini, Keikawus Arastéh, Christine Zurawski, Craig Dietz, Dennis Pontani, Will Garner, Thai Nguyen	2014	3
19	Maralixibat leads to significant reductions in pruritus and improvements in sleep for children with progressive familial intrahepatic cholestasis: data from MARCH-PFIC Journal of Hepatology ·Richard Thompson, Douglas B. Mogul, Tiago Nunes, Will Garner, Pamela Vig, Alexander Gerhard Miethke	2023	3
20	Viral Blips were Infrequent in Treatment-Naive Adults Treated with Rilpivirine/Emtricitabine/Tenofovir DF or Efavirenz/Emtricitabine/Tenofovir DF through 96 Weeks Antiviral Therapy ·Danielle Porter, Rima Kulkarni, Will Garner, Michael D. Miller, Kirsten White	2016	3

About Will Garner

Will Garner is a scholar working on Infectious Diseases, Hepatology, Surgery, Virology and Oncology, having authored 29 papers that have together received 833 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (12 papers), Pediatric Hepatobiliary Diseases and Treatments (7 papers), Liver Diseases and Immunity (5 papers), Drug Transport and Resistance Mechanisms (3 papers), HIV Research and Treatment (2 papers), Fungal Infections and Studies (1 paper), interferon and immune responses (1 paper) and Pneumocystis jirovecii pneumonia detection and treatment (1 paper). The work is most often cited by research in Virology (199 citations), Infectious Diseases (474 citations), Emergency Medicine (130 citations), Hepatology (112 citations) and Oncology (115 citations). Will Garner has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Anton Louis Pozniak, Kirsten White, Erin K. Quirk, Andrew Cheng, Andrea Antinori, Hans-Jürgen Stellbrink, Kimberly Workowski, Edwin DeJesus, Marisa Montes and Devi SenGupta. Their work appears in journals such as Journal of the International AIDS Society, Patient, Journal of Hepatology, AIDS and Digestive and Liver Disease.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Will Garner

Impact in

Papers in i

In The Last Decade

Will Garner

Will Garner's Hit Papers

Peers

Countries citing papers authored by Will Garner

Fields of papers citing papers by Will Garner

All Works

About Will Garner

Explore authors with similar magnitude of impact

Papers in